Transfusion medicine service policies for recombinant factor VIIa administration.
about
Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophiliaRecombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophiliaRational Use of Recombinant Factor VIIa in Clinical PracticeOff-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital recordsOff-label recombinant factor VIIa use and thrombosis in children: a multi-center cohort study.Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settingsRecombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trialsEvaluation of recombinant factor VIIa treatment for massive hemorrhage in patients with multiple traumasUse of activated recombinant factor VII for severe coagulopathy post ventricular assist device or orthotopic heart transplantRecombinant factor VIIa as an adjunctive therapy for patients requiring large volume transfusion: a pharmacoeconomic evaluation.Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma.Recombinant activated factor VII and the anaesthetist.The emerging role of recombinant activated Factor VII (rFVIIa) in the treatment of blunt traumatic haemorrhage.Recombinant factor VIIa: unregulated continuous use in patients with bleeding and coagulopathy does not alter mortality and outcome.Update on transfusion medicine.A review of transfusion risks and optimal management of perioperative bleeding with cardiac surgery.Salvage use of activated recombinant factor VII in the management of refractory bleeding following cardiac surgery.Iron Overload and Platelet Function Defects: Possible Correlation.Blood conservation strategies to reduce the need for red blood cell transfusion in critically ill patients.Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding--a European perspective.Recombinant activated factor VII in cardiac surgery: single-center experience.Utilization of recombinant activated factor VII in southern Ontario in 85 patients with and without haemophilia.How we treat: management of life-threatening primary postpartum hemorrhage with a standardized massive transfusion protocol.Practical considerations when developing guidelines for managing critical bleeding.Perioperative management of the bleeding patient.Recombinant Factor VIIA.
P2860
Q24236583-BC684B09-D7A5-4919-9B61-9AECBC42680EQ24245204-5CE2E5E5-57F5-4F6F-91C6-DEB6BF324B45Q26829915-A901CF7A-FB9D-40DB-B2CD-0C8424FAB707Q33571590-5182129E-FA91-4BCB-AA77-C6EB9A40C3F3Q34786006-A3CD84A6-A725-4176-B922-6FD2327C2A1EQ35578941-03C64B33-3DEF-44AF-8E17-ADC5CAB1B7CDQ35629970-2D78A37E-1B47-482A-8D03-53AC5BC06CA3Q35788608-E9DE9613-31CE-4F6A-8B60-5B52B4900886Q35924900-A5D79AA6-DF4F-46DB-A885-8B0513E1C371Q36263655-02DC179A-AB30-4FBD-A624-FDF61C6B5DC5Q36284640-3B375914-5663-4883-B640-5640E24D1ABEQ36313315-91832968-BA76-4907-9CEC-D361B19A013AQ36349573-1D33C6A5-ACA8-40C3-9F9A-79B5D1665EE5Q36603284-0CF39558-C946-4C6C-A0E3-CCCE0BCEB88CQ36920718-D9DA692F-F22F-46C0-BF3D-4B716AC03DE5Q37095548-6D73E2EA-8531-4C46-AF1F-205E48F3AE9CQ37979787-E22318FE-6904-42FC-929A-851D504BC01BQ41605854-67AD7ECE-2A29-465B-99B2-6FE0904495E1Q42111692-04FC0B73-7035-400A-8B18-6C5FA40F9F3AQ43055091-A09BC59A-C94D-4A1C-A9FD-2EEF457E0EB0Q45396991-27623814-3843-4716-B72F-880B16016ED9Q45871229-D9E97A97-938C-4104-AF09-BAB899061B7CQ46060644-04CF1454-EECC-4353-A336-A644C7EBF50EQ48387036-EA10CB84-8C62-4798-8A39-8DEC60EB940DQ50312912-EB41C467-8CCB-4AE1-9FFC-66C33767732DQ54920142-9817F4FA-E8A8-437A-A65E-8127383CC7D7
P2860
Transfusion medicine service policies for recombinant factor VIIa administration.
description
2004 nî lūn-bûn
@nan
2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Transfusion medicine service policies for recombinant factor VIIa administration.
@ast
Transfusion medicine service policies for recombinant factor VIIa administration.
@en
type
label
Transfusion medicine service policies for recombinant factor VIIa administration.
@ast
Transfusion medicine service policies for recombinant factor VIIa administration.
@en
prefLabel
Transfusion medicine service policies for recombinant factor VIIa administration.
@ast
Transfusion medicine service policies for recombinant factor VIIa administration.
@en
P2093
P2860
P1433
P1476
Transfusion medicine service policies for recombinant factor VIIa administration.
@en
P2093
Charles Eby
Douglas M Lublin
George Despotis
Lawrence Tim Goodnough
Lini Zhang
P2860
P304
P356
10.1111/J.1537-2995.2004.04052.X
P577
2004-09-01T00:00:00Z